Generic placeholder image

Current Drug Safety

Author(s): Syed Nasir Abbas Bukhari*

DOI: 10.2174/1574886317666220216101106

DownloadDownload PDF Flyer Cite As
Consequences of Antipsychotic Medications on Mental Health

Page: [285 - 293] Pages: 9

  • * (Excluding Mailing and Handling)

Abstract

Individuals suffering from mental illnesses, unfortunately, have a shorter lifespan. An increase in mortality rates is primarily due to physical illness, unhealthy lifestyle, and associated comorbidities. Antipsychotic medications, previously known as tranquilizers, antipsychotics, or neuroleptics, can alleviate or attenuate symptoms related to psychosis, delusion, and/or hallucinations and are used in the treatment of psychosis, schizophrenia, bipolar disorder, depression, or Alzheimer's disease. Within hours to days, these medications alleviate symptoms and reduce confusion in individuals with psychosis; however, the full effect may take longer than usual in some cases. Importantly, these drugs do not cure the disease, but only treat the symptoms of the disease. The treatment is adjusted to reduce any psychotic symptoms while keeping the adverse effects to a minimum level. Antipsychotics may lead to increased risk of diseases, including but not limited to, diabetes, obesity, metabolic disorders, cardiovascular, renal, or respiratory disorders. Improved dosages, polypharmacy, and age-specific treatment play an important role in limiting the comorbidities, as well as the side effects. Further research and clinical attention are required to understand the functioning of these medications. The review focuses on the use of antipsychotic medications in different diseases and their effect on mental health.

Keywords: Antipsychotic drugs, schizophrenia, bipolar disorder, dementia, mental illness, comorbidities.

Graphical Abstract

[1]
Hill SK, Reilly JL, Harris MSH, et al. A comparison of neu-ropsychological dysfunction in first-episode psychosis pa-tients with unipolar depression, bipolar disorder, and schizo-phrenia. Schizophr Res 2009; 113(2-3): 167-75.
[http://dx.doi.org/10.1016/j.schres.2009.04.020] [PMID: 19450952]
[2]
Lieberman JA, First MB. Psychotic disorders. N Engl J Med 2018; 379(3): 270-80.
[http://dx.doi.org/10.1056/NEJMra1801490] [PMID: 30021088]
[3]
Solmi M, Murru A, Pacchiarotti I, et al. Safety, tolerability, and risks associated with first- and second-generation anti-psychotics: A state-of-the-art clinical review. Ther Clin Risk Manag 2017; 13: 757-77.
[http://dx.doi.org/10.2147/TCRM.S117321] [PMID: 28721057]
[4]
Aringhieri S, Carli M, Kolachalam S, et al. Molecular targets of atypical antipsychotics: From mechanism of action to clini-cal differences. Pharmacol Ther 2018; 192: 20-41.
[http://dx.doi.org/10.1016/j.pharmthera.2018.06.012] [PMID: 29953902]
[5]
Friedman JH, Factor SA. Atypical antipsychotics in the treat-ment of drug-induced psychosis in Parkinson’s disease. Mov Disord 2000; 15(2): 201-11.
[http://dx.doi.org/10.1002/1531-8257(200003)15:2<201:AID-MDS1001>3.0.CO;2-D] [PMID: 10752567]
[6]
Gill SS, Rochon PA, Herrmann N, et al. Atypical antipsychot-ic drugs and risk of ischaemic stroke: population based retro-spective cohort study. BMJ 2005; 330(7489): 445.
[http://dx.doi.org/10.1136/bmj.38330.470486.8F] [PMID: 15668211]
[7]
Mittal V, Kurup L, Williamson D, Muralee S, Tampi RR. Risk of cerebrovascular adverse events and death in elderly pa-tients with dementia when treated with antipsychotic medica-tions: A literature review of evidence. Am J Alzheimers Dis Other Demen 2011; 26(1): 10-28.
[http://dx.doi.org/10.1177/1533317510390351] [PMID: 21282274]
[8]
Murray-Thomas T, Jones ME, Patel D, et al. Risk of mortality (including sudden cardiac death) and major cardiovascular events in atypical and typical antipsychotic users: A study with the general practice research database. Cardiovasc Psychiatry Neurol 2013; 2013: 247486.
[http://dx.doi.org/10.1155/2013/247486] [PMID: 24455199]
[9]
Bablenis E, Weber SS, Wagner RL. Clozapine: A novel anti-psychotic agent. DICP 1989; 23(2): 109-15.
[http://dx.doi.org/10.1177/106002808902300201] [PMID: 2658370]
[10]
Macdonald GJ, Bartolomé JM. Progress in Medicinal Chemistry. Amsterdam: Elsevier 2010; 49: 37-80.
[11]
Willins DL, Berry SA, Alsayegh L, et al. Clozapine and other 5-hydroxytryptamine-2A receptor antagonists alter the sub-cellular distribution of 5-hydroxytryptamine-2A receptors in vitro and in vivo. Neuroscience 1999; 91(2): 599-606.
[http://dx.doi.org/10.1016/S0306-4522(98)00653-8] [PMID: 10366017]
[12]
Oyesanmi O, Kunkel EJS, Monti DA, Field HL. Hematologic side effects of psychotropics. Psychosomatics 1999; 40(5): 414-21.
[http://dx.doi.org/10.1016/S0033-3182(99)71206-5] [PMID: 10479946]
[13]
Wetterling T. Bodyweight gain with atypical antipsychotics. A comparative review. Drug Saf 2001; 24(1): 59-73.
[http://dx.doi.org/10.2165/00002018-200124010-00005] [PMID: 11219487]
[14]
Cha DS, McIntyre RS. Treatment-emergent adverse events associated with atypical antipsychotics. Expert Opin Pharmacother 2012; 13(11): 1587-98.
[http://dx.doi.org/10.1517/14656566.2012.656590] [PMID: 22304541]
[15]
Keks NA. Minimizing the non-extrapyramidal side-effects of antipsychotics. Acta Psychiatr Scand Suppl 1996; 389(s389): 18-24.
[http://dx.doi.org/10.1111/j.1600-0447.1996.tb05944.x] [PMID: 8985473]
[16]
Kuroki T, Nagao N, Nakahara T. Neuropharmacology of second generation antipsychotic drugs: A validity of the serotonindopamine hypothesis. In: Esposito E, Di Matteo V, Di Giovanni G, Eds. Progress in Brain Research. Amsterdam: Elsevier 2008; 172: 199-212.
[17]
Di Giovanni G, Di Matteo V, Esposito E. Serotonin-dopamine interaction: An overview. In: Esposito E, Di Matteo V, Di Giovann G, Eds. Progress in Brain Research. Amsterdam: Elsevier 2008; 172: 3-6.
[18]
Karl T, Duffy L, O’brien E, Matsumoto I, Dedova I. Behav-ioural effects of chronic haloperidol and risperidone treatment in rats. Behav Brain Res 2006; 171(2): 286-94.
[http://dx.doi.org/10.1016/j.bbr.2006.04.004] [PMID: 16697060]
[19]
Rief W, Barsky AJ, Bingel U, et al. Rethinking psychophar-macotherapy: The role of treatment context and brain plastici-ty in antidepressant and antipsychotic interventions. Neurosci Biobehav Rev 2016; 60: 51-64.
[http://dx.doi.org/10.1016/j.neubiorev.2015.11.008] [PMID: 26616735]
[20]
Mitchell ES, Neumaier JF. 5-HT6 receptors: A novel target for cognitive enhancement. Pharmacol Ther 2005; 108(3): 320-33.
[http://dx.doi.org/10.1016/j.pharmthera.2005.05.001] [PMID: 16005519]
[21]
Celada P, Bortolozzi A, Artigas F. Serotonin 5-HT1A recep-tors as targets for agents to treat psychiatric disorders: Ra-tionale and current status of research. CNS Drugs 2013; 27(9): 703-16.
[http://dx.doi.org/10.1007/s40263-013-0071-0] [PMID: 23757185]
[22]
Manvich DF, Petko AK, Branco RC, et al. Selective D2 and D3 receptor antagonists oppositely modulate cocaine responses in mice via distinct postsynaptic mechanisms in nucleus ac-cumbens. Neuropsychopharmacology 2019; 44(8): 1445-55.
[http://dx.doi.org/10.1038/s41386-019-0371-2] [PMID: 30879021]
[23]
Flanagan RJ. Side effects of clozapine and some other psy-choactive drugs. Curr Drug Saf 2008; 3(2): 115-22.
[http://dx.doi.org/10.2174/157488608784529251] [PMID: 18690989]
[24]
Miller R. Mechanisms of action of antipsychotic drugs of different classes, refractoriness to therapeutic effects of clas-sical neuroleptics, and individual variation in sensitivity to their actions: Part I. Curr Neuropharmacol 2009; 7(4): 302-14.
[http://dx.doi.org/10.2174/157015909790031229] [PMID: 20514210]
[25]
Seeman P, Kapur S. Schizophrenia: More dopamine, more D2 receptors. Proc Natl Acad Sci USA 2000; 97(14): 7673-5.
[http://dx.doi.org/10.1073/pnas.97.14.7673] [PMID: 10884398]
[26]
Horacek J, Bubenikova-Valesova V, Kopecek M, et al. Mech-anism of action of atypical antipsychotic drugs and the neu-robiology of schizophrenia. CNS Drugs 2006; 20(5): 389-409.
[http://dx.doi.org/10.2165/00023210-200620050-00004] [PMID: 16696579]
[27]
Möller H-J. Antipsychotic and antidepressive effects of sec-ond generation antipsychotics: Two different pharmacological mechanisms? Eur Arch Psychiatry Clin Neurosci 2005; 255(3): 190-201.
[http://dx.doi.org/10.1007/s00406-005-0587-5] [PMID: 15995903]
[28]
Advokat CD, Mayville EA, Matson JL. Side effect profiles of atypical antipsychotics, typical antipsychotics, or no psycho-tropic medications in persons with mental retardation. Res Dev Disabil 2000; 21(1): 75-84.
[http://dx.doi.org/10.1016/S0891-4222(99)00031-1] [PMID: 10750167]
[29]
Arana GW. An overview of side effects caused by typical antipsychotics. J Clin Psychiatry 2000; 61(Suppl. 8): 5-11.
[PMID: 10811237]
[30]
Ascher-Svanum H, Zhu B, Faries D, Landbloom R, Swartz M, Swanson J. Time to discontinuation of atypical versus typical antipsychotics in the naturalistic treatment of schizophrenia. BMC Psychiatry 2006; 6(1): 8.
[http://dx.doi.org/10.1186/1471-244X-6-8] [PMID: 16504026]
[31]
Gründer G, Heinze M, Cordes J, et al. Effects of first-generation antipsychotics versus second-generation antipsy-chotics on quality of life in schizophrenia: A double-blind, randomised study. Lancet Psychiatry 2016; 3(8): 717-29.
[http://dx.doi.org/10.1016/S2215-0366(16)00085-7] [PMID: 27265548]
[32]
Kinon BJ, Lieberman JA. Mechanisms of action of atypical antipsychotic drugs: A critical analysis. Psychopharmacology (Berl) 1996; 124(1-2): 2-34.
[http://dx.doi.org/10.1007/BF02245602] [PMID: 8935797]
[33]
Abbas AI, Hedlund PB, Huang X-P, Tran TB, Meltzer HY, Roth BL. Amisulpride is a potent 5-HT7 antagonist: relevance for antidepressant actions in vivo. Psychopharmacology (Berl) 2009; 205(1): 119-28.
[http://dx.doi.org/10.1007/s00213-009-1521-8] [PMID: 19337725]
[34]
Juruena MF, de Sena EP, de Oliveira IR. Safety and tolerabil-ity of antipsychotics: focus on amisulpride. Drug Healthc Patient Saf 2010; 2: 205-11.
[http://dx.doi.org/10.2147/DHPS.S6226] [PMID: 21701632]
[35]
Komossa K. Rummel‐Kluge C, Hunger H, et al. Amisulpride versus other atypical antipsychotics for schizophrenia. Cochrane Database Syst Rev 2010; 1: CD006624.
[http://dx.doi.org/10.1002/14651858.CD006624.pub2]
[36]
Divac N, Prostran M, Jakovcevski I, Cerovac N. Second-generation antipsychotics and extrapyramidal adverse effects. BioMed Res Int 2014; 2014: 656370.
[http://dx.doi.org/10.1155/2014/656370] [PMID: 24995318]
[37]
de Bartolomeis A, Tomasetti C, Iasevoli F. Update on the mechanism of action of aripiprazole: Translational insights in-to antipsychotic strategies beyond dopamine receptor antago-nism. CNS Drugs 2015; 29(9): 773-99.
[http://dx.doi.org/10.1007/s40263-015-0278-3] [PMID: 26346901]
[38]
Di Sciascio G, Riva MA. Aripiprazole: From pharmacological profile to clinical use. Neuropsychiatr Dis Treat 2015; 11: 2635-47.
[PMID: 26508859]
[39]
Adan-Manes J, Garcia-Parajua P. Aripiprazole in combination with other antipsychotic drugs may worsen psychosis. J Clin Pharm Ther 2009; 34(2): 245-6.
[http://dx.doi.org/10.1111/j.1365-2710.2008.00996.x] [PMID: 19250146]
[40]
Lieberman JA. Is schizophrenia a neurodegenerative disor-der? A clinical and neurobiological perspective. Biol Psychiatry 1999; 46(6): 729-39.
[http://dx.doi.org/10.1016/S0006-3223(99)00147-X] [PMID: 10494440]
[41]
Tiihonen J, Lönnqvist J, Wahlbeck K, et al. 11-Year follow-up of mortality in patients with schizophrenia: A population-based cohort study (FIN11 study). Lancet 2009; 374(9690): 620-7.
[http://dx.doi.org/10.1016/S0140-6736(09)60742-X] [PMID: 19595447]
[42]
Olfson M, Gerhard T, Huang C, Crystal S, Stroup TS. Prema-ture mortality among adults with schizophrenia in the United States. JAMA Psychiatry 2015; 72(12): 1172-81.
[http://dx.doi.org/10.1001/jamapsychiatry.2015.1737] [PMID: 26509694]
[43]
Brown S, Inskip H, Barraclough B. Causes of the excess mor-tality of schizophrenia. Br J Psychiatry 2000; 177(3): 212-7.
[http://dx.doi.org/10.1192/bjp.177.3.212] [PMID: 11040880]
[44]
Ceraso A, Lin JJ, Schneider-Thoma J, et al. Maintenance treatment with antipsychotic drugs for schizophrenia. Cochrane Database Syst Rev 2020; 8: CD008016.
[45]
Chen Y, Yang X, Qin X, et al. Antipsychotics and risk of natural death in patients with schizophrenia. Neuropsychiatr Dis Treat 2019; 15: 1863-71.
[http://dx.doi.org/10.2147/NDT.S199748] [PMID: 31308678]
[46]
Weinmann S, Aderhold V, Müller-Oerlinghausen B. Influence of antipsychotics on mortality in schizophrenia: Evidence from observational studies. Pharmacopsychiatry 2009; 42(05): A177.
[http://dx.doi.org/10.1055/s-0029-1240249]
[47]
Bhattacharjee J. El-Sayeh HG. Aripiprazole versus typical antipsychotic drugs for schizophrenia. Cochrane Database Syst Rev 2008; 2008(3): CD006617.
[http://dx.doi.org/10.1002/14651858.CD006617.pub3]
[48]
García S, Martínez-Cengotitabengoa M, López-Zurbano S, et al. Adherence to antipsychotic medication in bipolar disorder and schizophrenic patients: A systematic review. J Clin Psychopharmacol 2016; 36(4): 355-71.
[http://dx.doi.org/10.1097/JCP.0000000000000523] [PMID: 27307187]
[49]
Haddad PM, Sharma SG. Adverse effects of atypical antipsy-chotics: Differential risk and clinical implications. CNS Drugs 2007; 21(11): 911-36.
[http://dx.doi.org/10.2165/00023210-200721110-00004] [PMID: 17927296]
[50]
Yumru M, Savas HA, Kurt E, et al. Atypical antipsychotics related metabolic syndrome in bipolar patients. J Affect Disord 2007; 98(3): 247-52.
[http://dx.doi.org/10.1016/j.jad.2006.08.009] [PMID: 16970993]
[51]
Vieta E, Sanchez-Moreno J. Acute and long-term treatment of mania. Dialogues Clin Neurosci 2008; 10(2): 165-79.
[http://dx.doi.org/10.31887/DCNS.2008.10.2/evieta] [PMID: 18689287]
[52]
Scherk H, Pajonk FG, Leucht S. Second-generation antipsy-chotic agents in the treatment of acute mania: A systematic re-view and meta-analysis of randomized controlled trials. Arch Gen Psychiatry 2007; 64(4): 442-55.
[http://dx.doi.org/10.1001/archpsyc.64.4.442] [PMID: 17404121]
[53]
Wolfsperger M, Greil W, Rössler W, Grohmann R. Pharmaco-logical treatment of acute mania in psychiatric in-patients be-tween 1994 and 2004. J Affect Disord 2007; 99(1-3): 9-17.
[http://dx.doi.org/10.1016/j.jad.2006.08.017] [PMID: 16989907]
[54]
Selle V, Schalkwijk S, Vázquez GH, Baldessarini RJ. Treat-ments for acute bipolar depression: Meta-analyses of place-bo-controlled, monotherapy trials of anticonvulsants, lithium and antipsychotics. Pharmacopsychiatry 2014; 47(2): 43-52.
[http://dx.doi.org/10.1055/s-0033-1363258] [PMID: 24549862]
[55]
Brugue E, Vieta E. Atypical antipsychotics in bipolar depres-sion: Neurobiological basis and clinical implications. Prog Neuropsychopharmacol Biol Psychiatry 2007; 31(1): 275-82.
[http://dx.doi.org/10.1016/j.pnpbp.2006.06.014] [PMID: 16876306]
[56]
Nelson JC, Papakostas GI. Atypical antipsychotic augmenta-tion in major depressive disorder: A meta-analysis of place-bo-controlled randomized trials. Am J Psychiatry 2009; 166(9): 980-91.
[http://dx.doi.org/10.1176/appi.ajp.2009.09030312] [PMID: 19687129]
[57]
Gao K, Gajwani P, Elhaj O, Calabrese JR. Typical and atypical antipsychotics in bipolar depression. J Clin Psychiatry 2005; 66(11): 1376-85.
[http://dx.doi.org/10.4088/JCP.v66n1106] [PMID: 16420074]
[58]
Cerejeira J, Lagarto L, Mukaetova-Ladinska EB. Behavioral and psychological symptoms of dementia. Front Neurol 2012; 3(73): 73.
[PMID: 22586419]
[59]
Ballard C, Smith J, Husebo B, Aarsland D, Corbett A. The role of pain treatment in managing the behavioural and psycholog-ical symptoms of dementia (BPSD). Int J Palliat Nurs 2011; 17(9): 420-4.
[http://dx.doi.org/10.12968/ijpn.2011.17.9.420] [PMID: 22067732]
[60]
Tible OP, Riese F, Savaskan E, von Gunten A. Best practice in the management of behavioural and psychological symptoms of dementia. Ther Adv Neurol Disord 2017; 10(8): 297-309.
[http://dx.doi.org/10.1177/1756285617712979] [PMID: 28781611]
[61]
Pink J, O’Brien J, Robinson L, Longson D. Dementia: As-sessment, management and support: Summary of updated NICE guidance. BMJ 2018; 361: k2438.
[http://dx.doi.org/10.1136/bmj.k2438] [PMID: 29925626]